166 related articles for article (PubMed ID: 38022521)
1. Novel nomogram for predicting survival in advanced non-small cell lung cancer receiving anti-PD-1 plus chemotherapy with or without antiangiogenic therapy.
Wu Y; Lv C; Lin M; Hong Y; Du B; Yao N; Zhu Y; Ji X; Li J; Lai J
Front Immunol; 2023; 14():1297188. PubMed ID: 38022521
[TBL] [Abstract][Full Text] [Related]
2. [Construction of A Nomogram Prediction Model for PD-L1 Expression
in Non-small Cell Lung Cancer Based on 18F-FDG PET/CT Metabolic Parameters].
Hao L; Wang L; Zhang M; Yan J; Zhang F
Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):833-842. PubMed ID: 38061885
[TBL] [Abstract][Full Text] [Related]
3. Development of nomograms to predict therapeutic response and prognosis of non-small cell lung cancer patients treated with anti-PD-1 antibody.
Yuan S; Xia Y; Shen L; Ye L; Li L; Chen L; Xie X; Lou H; Zhang J
Cancer Immunol Immunother; 2021 Feb; 70(2):533-546. PubMed ID: 32852602
[TBL] [Abstract][Full Text] [Related]
4. Nomograms integrating CT radiomic and deep learning signatures to predict overall survival and progression-free survival in NSCLC patients treated with chemotherapy.
Chang R; Qi S; Wu Y; Yue Y; Zhang X; Qian W
Cancer Imaging; 2023 Oct; 23(1):101. PubMed ID: 37867196
[TBL] [Abstract][Full Text] [Related]
5. Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer.
Zheng L; Hu F; Huang L; Lu J; Yang X; Xu J; Wang S; Shen Y; Zhong R; Chu T; Zhang W; Li Y; Zheng X; Han B; Zhong H; Nie W; Zhang X
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38641349
[TBL] [Abstract][Full Text] [Related]
6. A nomogram model for predicting the risk of checkpoint inhibitor-related pneumonitis for patients with advanced non-small-cell lung cancer.
Zhang Y; Zhang L; Cao S; Wang Y; Ling X; Zhou Y; Zhong H
Cancer Med; 2023 Aug; 12(15):15998-16010. PubMed ID: 37409360
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 Protein Expression Is Associated With Good Clinical Outcomes and Nomogram for Prediction of Disease Free Survival and Overall Survival in Breast Cancer Patients Received Neoadjuvant Chemotherapy.
Chen L; Huang S; Liu Q; Kong X; Su Z; Zhu M; Fang Y; Zhang L; Li X; Wang J
Front Immunol; 2022; 13():849468. PubMed ID: 35669769
[TBL] [Abstract][Full Text] [Related]
8. A prognostic model for predicting progression-free survival in patients with advanced non-small cell lung cancer after image-guided microwave ablation plus chemotherapy.
Kong F; Yang H; Wang Q; Wei Z; Ye X
Eur Radiol; 2023 Nov; 33(11):7438-7449. PubMed ID: 37318606
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a nomogram for predicting overall survival of resected N2 non-small cell lung cancer patients undergoing neoadjuvant radiotherapy.
Shi J; Peng B; Wang C; Zhou X; Lu T; Xu R; Chang X; Shen Z; Wang K; Xu C; Zhang L
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11779-11790. PubMed ID: 37407846
[TBL] [Abstract][Full Text] [Related]
10. Establishment of prognostic nomograms for predicting the progression free survival of EGFR-sensitizing mutation, advanced lung cancer patients treated with EGFR-TKIs.
Du X; Bai H; Wang Z; Daun J; Liu Z; Xu J; Chang G; Zhu Y; Wang J
Thorac Cancer; 2022 May; 13(9):1289-1298. PubMed ID: 35347870
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum lactate dehydrogenase to albumin ratio is a useful poor prognostic predictor of nivolumab in patients with non-small cell lung cancer.
Menekse S; Kut E; Almuradova E
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(5 Suppl):86-94. PubMed ID: 37869953
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a nomogram for evaluating the prognosis of immunotherapy plus antiangiogenic therapy in non-small cell lung cancer.
Huang H; Chen Y; Weng X; Li S; Zhang L; Chen P
Cancer Cell Int; 2022 Aug; 22(1):261. PubMed ID: 35989349
[TBL] [Abstract][Full Text] [Related]
14. The Nomogram predicting the overall survival of patients with pancreatic cancer treated with radiotherapy: a study based on the SEER database and a Chinese cohort.
Dong X; Wang K; Yang H; Cheng R; Li Y; Hou Y; Chang J; Yuan L
Front Endocrinol (Lausanne); 2023; 14():1266318. PubMed ID: 37955009
[TBL] [Abstract][Full Text] [Related]
15. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
16. Nomograms based on the lymphocyte-albumin-neutrophil ratio (LANR) for predicting the prognosis of nasopharyngeal carcinoma patients after definitive radiotherapy.
Zhang S; Chen Z; Ling J; Feng Y; Xie Y; Liu X; Hu C; Hou T
Sci Rep; 2024 Mar; 14(1):5388. PubMed ID: 38443675
[TBL] [Abstract][Full Text] [Related]
17. Construction and Validation of a Novel Nomogram to Predict the Overall Survival of Patients With Combined Small Cell Lung Cancer: A Surveillance, Epidemiology, and End Results Population-Based Study.
Jiang A; Liu N; Zhao R; Liu S; Gao H; Wang J; Zheng X; Ren M; Fu X; Liang X; Tian T; Ruan Z; Yao Y
Cancer Control; 2021; 28():10732748211051228. PubMed ID: 34632799
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic value of skeletal muscle measured by CT at the T4 level in advanced EGFR-positive non-small cell lung cancer patients treated with ecotinib].
Xia H; Tan XY; Lu XT; Wang SF; Cao YQ; Luo P; Song SW; Guo MF; Yang L; Jin Y
Zhonghua Yi Xue Za Zhi; 2024 May; 104(18):1590-1600. PubMed ID: 38742346
[No Abstract] [Full Text] [Related]
19. Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Zeng H; Huang WW; Liu YJ; Huang Q; Zhao SM; Li YL; Tian PW; Li WM
Front Oncol; 2021; 11():685047. PubMed ID: 34458139
[TBL] [Abstract][Full Text] [Related]
20. Nomogram Based on Lactate Dehydrogenase-to-Albumin Ratio (LAR) and Platelet-to-Lymphocyte Ratio (PLR) for Predicting Survival in Nasopharyngeal Carcinoma.
Peng RR; Liang ZG; Chen KH; Li L; Qu S; Zhu XD
J Inflamm Res; 2021; 14():4019-4033. PubMed ID: 34447260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
